D&D Pharmatech Inc
347850
Company Profile
Business description
D&D Pharmatech Inc is building on a robust foundation of proprietary peptide research and strategic collaborations. The group is advancing a diverse pipeline of therapeutics for metabolic, fibrotic, and neurodegenerative diseases. The world-wide biotech company's umbrella structure comprises three U.S. subsidiaries, which include its clinical research arm responsible for conducting clinical trials for the company's pipeline, including its dual agonist (GLP-1/glucagon) for metabolic dysfunction-associated steatohepatitis (MASH).
Contact
27, Geumto-ro 80beon-gil
4th floor, Geumto-dong
Sujeong-gu, Gyeonggi-do
Seongnam-si13454
KORT: +82 3180197771
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
21
Stocks News & Analysis
stocks
ASX healthcare share remains undervalued ahead of earnings
Margin recovery remains the key driver for this ASX healthcare share.
stocks
Alphabet earnings: Strong AI monetization continues to spearhead results
We maintain our fair value estimate for wide-moat Alphabet.
stocks
AMD: We’re pleased with Anthropic Partnership ahead of advancing AI event
We’re encouraged that AMD will count Anthropic as a third leading AI customer, in addition to OpenAI and Meta.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,941.50 | 32.70 | -0.36% |
| CAC 40 | 8,336.64 | 37.55 | 0.45% |
| DAX 40 | 24,986.25 | 223.13 | 0.90% |
| Dow JONES (US) | 51,861.45 | 149.80 | 0.29% |
| FTSE 100 | 10,712.55 | 73.38 | 0.69% |
| HKSE | 24,963.23 | 247.58 | -0.98% |
| NASDAQ | 25,046.97 | 90.72 | -0.36% |
| Nikkei 225 | 64,611.15 | 1,811.45 | -2.73% |
| NZX 50 Index | 13,772.29 | 23.02 | -0.17% |
| S&P 500 | 7,426.52 | 18.22 | 0.25% |
| S&P/ASX 200 | 8,772.30 | 23.40 | -0.27% |
| SSE Composite Index | 3,814.20 | 62.58 | -1.61% |